Dogwood Therapeutics (DWTX) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability
2. 02We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of Halneuron®, IMC-1 or IMC-2
3. 03Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
4. 04Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations
5. 05We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability

Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

1. 06We are heavily dependent on the success of our product candidates, Halneuron®, IMC-1 and IMC-2, which are still under clinical development, and if these candidates do not receive regulatory approval or, if approved, our commercialization efforts are unsuccessful, our business may be harmed
2. 07The development of our product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease
3. 08Clinical trials are expensive, time-consuming and difficult to design and implement and involve an uncertain outcome
4. 09The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for Halneuron®, IMC-1, IMC-2 or any other product candidates, our business will be substantially harmed
5. 10Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control
6. 11Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials
7. 12the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly
8. 13The market opportunities for Halneuron®, IMC-1 or IMC-2, if approved, may be smaller than we anticipate
9. 14We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates
10. 15outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business
11. 16Even if we obtain regulatory approval for Halneuron®, IMC-1, IMC-2 or any other product candidate, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties
12. 17We may seek a Breakthrough Therapy designation for Halneuron®, IMC-1 or IMC-2 from the FDA. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process
13. 18Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop

Risks Related to Commercialization

1. 19We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively
2. 20We may face early generic competition for Halneuron®, IMC-1, IMC-2 or any other products we successfully develop and market
3. 21Even if Halneuron®, IMC-1, IMC-2 or any other product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success
4. 22If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing Halneuron®, IMC-1 or IMC-2, if approved
5. 23A variety of risks associated with operating internationally could materially adversely affect our business

Risks Related to Our Dependence on Third Parties

1. 24We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business

Risks Related to Healthcare Laws and Other Legal Compliance Matters

1. 25Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set
2. 26Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
3. 27Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation
4. 28We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities
5. 29If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations

Risks Related to Our Intellectual Property

1. 30Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours
2. 31We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates
3. 32relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates
4. 33Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
5. 34Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 35We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
7. 36If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed
8. 37Intellectual property rights do not address all potential threats to our competitive advantage
9. 38If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
10. 39We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
11. 40We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties
12. 41Our proprietary information may be lost, or we may suffer security breaches

Risks Related to Our Employees, Managing Our Growth and Our Operations

1. 42Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
2. 43We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
3. 44We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources
4. 45Our business and operations would suffer in the event of system failures
5. 46We may be materially adversely affected by currency fluctuations in the United States dollar versus the Canadian dollar

Risks Related to Our Common Stock

1. 47If we are unable to maintain listing of our common stock on the Nasdaq Capital Market or another national stock exchange, it may be more difficult for our stockholders to sell their shares of common stock
2. 48The market price of our common stock is highly volatile, which could result in substantial losses for holders of our common stock
3. 49We could be subject to securities class action litigation
4. 50If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline
5. 51We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
6. 52We are subject to significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
7. 53If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed
8. 54We are an “emerging growth company,” and a “smaller reporting company” and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
9. 55Provisions in our certificate of incorporation and bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
10. 56Our certificate of incorporation and our bylaws will contain exclusive forum provisions for certain claims, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees
11. 57pursuant to the General Corporation Law of the State of Delaware, our certificate of incorporation, or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine

Risks Related to the Combination

1. 58There is no guarantee that the Combination will increase stockholder value
2. 59If our acquired intangible assets and goodwill become impaired, we may be required to record a significant charge to earnings
3. 60Tetrodotoxin and Halneuron® may become subject to a contractual repurchase right in certain circumstances, which could have a material adverse effect on our results of operations, financial condition, and cash flows
4. 61Pursuant to the terms of the Exchange Agreement, we are required to recommend that our stockholders approve the conversion of all outstanding shares of our Series A Non-Voting Convertible Preferred Stock into shares of our Common Stock. We cannot guarantee that our stockholders will approve this matter
5. 62The issuance of common stock upon conversion of our outstanding Series A Non-Voting Convertible Preferred Stock and Series A-1 Non-Voting Convertible Preferred Stock will cause immediate and substantial dilution to existing shareholders
6. 63We may be required to settle shares of Series A Non-Voting Convertible Preferred Stock for cash, which could have a material adverse effect on our business and financial condition
7. 64The failure to successfully integrate the businesses of the Company and Pharmagesic in the expected timeframe could adversely affect Dogwood’s results of operations, financial condition, and future results
8. 65Our future results will suffer if we do not effectively manage our expanded operations
9. 66We expect to incur substantial expenses related to the integration of Pharmagesic